INR targets and warfarin management
Gives the indication for a vitamin K antagonist and the target INR for each indication, ESC beside ACC/AHA: mechanical aortic and mitral valves by prosthesis thrombogenicity and patient risk factors (ESC 2021 table), the On-X lower target, the first 3 months after a bioprosthesis or repair, valvular AF with moderate–severe mitral stenosis, antiphospholipid syndrome (venous, arterial, recurrent), Fontan circulation, DVT/PE and LV thrombus, with the cases where a DOAC is contraindicated. With the current INR it says what to do: below range (dose increase, causes, heparin bridging for mechanical valves), above range (omit doses, oral vitamin K, PCC and IV vitamin K for major bleeding, when to restart), and before a procedure (continue for minor procedures, stop 5 days before surgery, bridging and restart).
- Target INR 2.5 (2.0–3.0)INo patient risk factor
- Target INR 2.5 (2.0–3.0)IBileaflet or current-generation tilting-disc valve, no risk factor
- Lifelong VKA for every mechanical valveIESC 2021 · ACC/AHA 2020Warfarin (or acenocoumarol, phenprocoumon). INR self-monitoring in trained patients; aim for a time in therapeutic range ≥ 70%.
- Do not use a DOAC with a mechanical valveIIIESC 2021 · ACC/AHA 2020Dabigatran (RE-ALIGN) and apixaban (PROACT Xa) caused more valve thrombosis and bleeding than warfarin.
| Indication | ESC | ACC/AHA |
|---|---|---|
| Mechanical aortic, low thrombogenicity, no risk factor | 2.5 | 2.5 |
| Mechanical aortic with a risk factor | 3.0 (low) · 3.5 (medium) · 4.0 (high) | 3.0 |
| Mechanical mitral / tricuspid | 3.0 (low) · 3.5 (medium) · 4.0 (high) | 3.0 |
| On-X aortic after 3 months, no risk factor | 2.5 | 1.5–2.0 + aspirin (IIb) |
| Bioprosthesis / repair, first 3 months | 2.5 (mitral, tricuspid) | 2.5 for 3–6 months |
| Valvular AF (moderate–severe MS) | 2.0–3.0 | 2.0–3.0 |
| APS venous · arterial | 2.0–3.0 · 2.0–3.0 + aspirin or 3.0–4.0 | EULAR 2019 |
| Fontan, DVT/PE, LV thrombus | 2.0–3.0 | 2.0–3.0 |
ESC patient risk factors: mitral or tricuspid replacement, previous thromboembolism, AF, mitral stenosis of any degree, LVEF < 35%. Range = target ± 0.5.
- Vahanian A, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561-632.
- Otto CM, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease. Circulation 2021;143:e72-e227.
- Praz F, et al. 2025 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2025.
- Van Gelder IC, et al. 2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2024;45:3314-3414.
- Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation. Circulation 2024;149:e1-e156.
- Connolly SJ, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation (INVICTUS). N Engl J Med 2022;387:978-988.
- Puskas J, et al. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the PROACT trial. J Thorac Cardiovasc Surg 2014;147:1202-1211.
- Tektonidou MG, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019;78:1296-1304.
- Baumgartner H, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021;42:563-645.
- Rychik J, et al. Evaluation and management of the child and adult with Fontan circulation: a scientific statement from the AHA. Circulation 2019;140:e234-e284.
- Holbrook A, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed (ACCP). Chest 2012;141:e152S-e184S.
- Keeling D, et al. Guidelines on oral anticoagulation with warfarin – fourth edition (BSH). Br J Haematol 2011;154:311-324.
- Tomaselli GF, et al. 2020 ACC Expert Consensus Decision Pathway on management of bleeding in patients on oral anticoagulants. J Am Coll Cardiol 2020;76:594-622.
- Douketis JD, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. Chest 2022;162:e207-e243.
- Halvorsen S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J 2022;43:3826-3924.
- Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:3720-3826.
- Konstantinides SV, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J 2020;41:543-603.
- LV systolic function — grade
- LV diastolic function — echo grading
- LV hypertrophy — mass & geometry
- Aortic stenosis — echo grading
- Aortic regurgitation — echo grading
- Mitral regurgitation — echo grading
- Mitral stenosis — echo grading
- Wilkins Score
- Prosthetic valve assessment
- Right ventricle, IVC & PH probability
- IVC — collapsibility & RA pressure